33115-66-1

Upstream product

• 695-34-1 2-Amino-4-methylpyridine 
• 586-75-4 4-chlorobenzoyl chloride 
• 586-76-5 4-Bromobenzoic acid 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 99-90-1 para-bromoacetophenone 

Relevant academic research and scientific papers

Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma

Ibrutinib, a potent irreversible Bruton's tyrosine kinase (BTK) inhibitor, was approved by the FDA for treating mantle cell lymphoma (MCL). Although ibrutinib exhibited excellent antitumor activity, it was associated with certain adverse reactions, with o

1-substituted benzyl pyrazolopyrimidine derivative, preparation method and applications thereof

The invention discloses a 1-substituted benzyl pyrazolopyrimidine derivative, a preparation method and applications thereof, wherein the structure of the 1-substituted benzyl pyrazolopyrimidine derivative is shown as a general formula I, a general formula II or a general formula III, R1 is selected from hydrogen, C1-6 linear chain or branched chain alkyl and trihalomethyl, R2 is selected from hydrogen, halogen, nitro, C1-6 linear chain or branched chain alkyl, trifluoromethyl and cyano, R3 is selected from amino, and R4 is selected from substituted amide group. The compound has a certain BTK inhibition activity.

Hydroxamic acid derivative containing pyrazolopyrimidine and preparation method and application thereof

The invention provides a hydroxamic acid derivative containing pyrazolopyrimidine and a preparation method and application thereof. The hydroxamic acid derivative containing pyrazolopyrimidine has a structure as shown in a formula I, in the formula I, X is selected from oxygen, acylamino and methylene; Y is selected from methine, substituted methine and nitrogen; Z is selected from methylene, benzyl, piperidyl, pyridyl, pyrrolidinyl, pyrimidinyl, imidazolyl and oxadiazolyl; the piperidyl is shown in the specification, or the carbon end of the piperidyl is connected with the nitrogen end of pyrazole; R is selected from hydrogen, halogen, nitro, amino, substituted amino, cyano, methyl, methoxy and trifluoromethyl; n is any integer from 0 to 7; and when X is oxygen, Y is methine, and Z is R and H, n is not 1. The compound shown in the formula I has BTK and/or HDAC inhibitory activity and has a good growth inhibition effect on lymphoma, especially mantle cell lymphoma.

Ru(II)-Catalyzed Oxidative Olefination of Benzamides: Switchable Aza-Michael and Aza-Wacker Reaction for Synthesis of Isoindolinones

Selective tandem oxidative C-H olefination-aza-Michael/aza-Wacker reaction of N-arylbenzamides is achieved by fine-tuning between base and additive to access valuable 3-oxoisoindolinyls and 3-oxoisoindolinylidenes, respectively. Careful optimization and c

Copper(II)-mediated, carbon degradation-based amidation of phenylacetic acids toward N -substituted benzamides

The unprecedented synthesis of N-aryl substituted benzamides via the assembly of primary amines and phenylacetic acids has been developed in the presence of copper(ii) acetate. This tandem transformation involving carbon-carbon bond cleavage provides a complementary tool with particular application in the synthesis of secondary benzamides.

NOVEL HYDRAZINO COMPOUNDS AS BTK INHIBITORS

The present invention relates to novel hydrazino compounds of Formula (I) as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders involving mediation of Bruton tyrosine kinase in humans.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Described herein are cyano containing heteroaryl compounds as kinase inhibitors. Methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases described.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

A one-pot copper catalyzed biomimetic route to n -heterocyclic amides from methyl ketones via oxidative c-c bond cleavage

A direct one-pot Cu-catalyzed biomimetic oxidation of methyl ketones to pharmaceutically important N-heterocyclic amides is reported. The scope of the method is broad, scalable, and mild, and the reaction is tolerant with various acid, base sensitive functionalities with multiple heteroatoms and aryl halides. The extensive mechanistic studies suggest that this reaction follows the Luciferin-Luciferase-like pathway.